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Abstract
Aim To provide an estimate of the annual cost of atrial
ﬁbrillation (AF) in Sweden.
Methods Prevalence-based cost analysis of AF in Sweden
for 2007. Direct medical (hospitalizations, hospital outpa-
tient care, primary health care, non-pharmacological
interventions, pharmaceuticals, and anticoagulation moni-
toring) and non-medical (transportation associated with
health care visits) costs of AF, direct costs of AF compli-
cations (stroke and heart failure), and indirect costs (pro-
duction loss), were included. Data were based on Swedish
registries, reports and databases, published literature, and
an expert panel.
Results There were 100,557 individuals with AF as pri-
mary or secondary diagnosis that were either hospitalized
or treated in hospital outpatient care in 2007. The total cost
of AF was estimated at €708 million. The major cost driver
was the direct cost of complications (54%), followed by
hospitalization due to AF including AF as secondary
diagnosis (18%), and production loss (12%).
Conclusion This is a comprehensive, nation-based cost
analysis of AF where relevant data were derived from
national registries covering the entire Swedish popula-
tion. The results showed that the annual cost of AF was
high in comparison with other diseases, but likely to be
underestimated as a conservative approach was applied
in the analysis.
Keywords Cost of illness  Direct costs  Indirect costs 
Atrial ﬁbrillation  Stroke  Heart failure
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Introduction
Atrial ﬁbrillation (AF) is the most common, clinically
signiﬁcant cardiac arrhythmia [1]. The prevalence in the
general population is approximately 1%, increasing to
nearly 10% among those over 80 [2]. The number of
patients suffering from AF is likely to increase in forth-
coming years as the proportion of elderly in the population
is rising [2, 3] in combination with improved survival
associated with concomitant diseases such as coronary
heart disease, stroke, and heart failure (HF) [4–8]. Conse-
quently, an increasing demand on resources for patients
with AF and its related diseases is to be expected. The
rationale for cost-of-illness studies is the contribution to
health care planning by providing information on costs for
managing patients with a speciﬁc disease.
Some studies have been published on the costs of AF
[9–13] where the results were based on data from a patient
sample subsequently extrapolated to the national level. In
contrast, the present study uses mainly nationwide data.
Several registries covering the entire Swedish population
([9 million people) have been maintained for many years
offering unique opportunities for research particularly as
the information is based on unique personal identiﬁcation
numbers. For the present study, the availability of observed
frequencies of hospitalizations from the Patient Registry at
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sick-leave listing from the Swedish Social Insurance
Agency were of particular interest. To our knowledge, no
previous study on the costs of AF has been based on such a
comprehensive approach. The objective of this study was
thus to estimate the annual costs of AF in Sweden by uti-
lizing available, population-based data, and by considering
the costs of both AF per se and the costs of its main
complications stroke and HF.
Methods
This study is a prevalence-based, cost-of-illness analysis
based on the entire Swedish population (n = 9,182,927).
Both the top-down approach, where national frequencies
and events formed the basis for estimates, and the bottom-
up approach, where costs for a deﬁned subpopulation were
estimated and then extrapolated to represent the entire
population, was used [14, 15].
Information not available in Swedish registries, reports
or databases, or in the published literature, was estimated
from individual telephone interviews with an expert panel,
including three cardiologists and two general practitioners
from different parts of Sweden. The questions posed were
related to treatment practices, such as hospital outpatient or
primary health care and pharmaceuticals.
All costs were estimated in SEK according to 2007
prices and then converted to Euros (€1.00 = SEK9.25)
and, where applicable, the consumer price index (CPI) was
applied as the conversion factor.
Diagnosis deﬁnitions
Diagnoses were deﬁned according to the ICD-10 classiﬁ-
cation system. AF was assessed both as primary and as
secondary diagnosis and the code I48 (I48.9), comprising
both atrial ﬁbrillation and ﬂutter, was used.
Stroke was deﬁned as either I63 ‘‘ischaemic stroke’’ or
I64 ‘‘unspeciﬁed stroke’’. HF was deﬁned as I50, which
includes the subgroups ‘‘congestive heart failure’’, ‘‘left
ventricular failure’’, and ‘‘unspeciﬁed heart failure’’.
Direct medical costs of atrial ﬁbrillation
The direct medical costs of AF included inpatient care
(hospitalization), hospital outpatient care (specialist visits),
primary health care (general practitioner visits), non-
pharmacological interventions (inpatient and outpatient
procedures), pharmacological treatment, and anticoagula-
tion monitoring. Data on hospitalization and hospital out-
patient care including non-pharmacological interventions,
as well as the average number of visits per patient yearly
were retrieved from the Patient Registry at the Swedish
National Board of Health and Welfare, and was based on
2007. This Registry does, however, not provide any pri-
mary health care data. The proportion of AF patients
treated in hospital outpatient and primary health care,
respectively, was assumed to be 50% in each setting
according to expert panel. That is, the estimated number of
primary health care visits applied in the present analysis
was equal to the number of hospital outpatient visits
retrieved from the Patient Registry.
The cost of AF as a secondary diagnosis was included in
the analysis. The number of hospitalizations for patients
with AF as secondary diagnosis was calculated as the
number of all hospitalizations with AF (primary and sec-
ondary) less the number of hospitalizations with AF as
primary diagnosis. This data were retrieved from the
Patient Registry, whereas the disorders and/or cardiovas-
cular risk factors analysed as primary diagnoses, with AF
as secondary diagnosis, were based on ﬁndings on what
were the most common concomitant diseases/risk factors
according to the Euro Heart Survey on Atrial Fibrillation
[16]. These diagnoses include hypertensive diseases,
ischaemic heart diseases, valvular heart diseases, diabetes
mellitus, and hyperlipidaemia. The occurrence of hospi-
talizations with AF listed as secondary diagnosis is thus
based on actual and on observed data, while the primary
diagnoses were assumed to reﬂect a common disease pro-
ﬁle of AF patients as evidenced in the literature. A detailed
analysis of these diagnoses was beyond the scope of the
present study. Stroke and HF were analysed separately.
The costs of hospitalization and interventions were
calculated according to the Diagnosed Related Groups
(DRG) classiﬁcation system. Costs for DRG weights were
obtained from the 2007 inpatient/outpatient list for the
Va ¨stra Go ¨taland Region (the greater south-western/western
area corresponding to 17% of the total Swedish popula-
tion). Costs of specialist or general practitioner visits were
obtained from a medical price list (‘‘Utomla ¨nsprislista’’)
from 2007 for the same region.
The percentage use of rate (digoxin, beta-blockers,
verapamil/diltiazem) and rhythm (sotalol, ﬂecainide/pro-
pafenone, disopyramide, amiodarone) control agents was
derived from the Auricula Registry, a Swedish national
quality registry of AF patients [17], whereas antithrombotic
(warfarin, ASA) treatment was based on estimates from
three Swedish studies [18–20]. Pharmaceutical prices were
taken from Pharmaceutical Specialties in Sweden (FASS)
[21]. Annual costs were calculated based on an estimated
prevalence of 140,000 AF patients (see below).
Concerning anticoagulation monitoring, an annual fre-
quency of 16.18 international normalized ratio (INR)
analyses per patient in primary health care was applied
from a previous study [22]. It was assumed that the same
480 L. Ericson et al.
123number of INR analyses was monitored at specialized
anticoagulation hospital clinics where 58% [18] of follow-
up was estimated to take place. The cost of monitoring at
anticoagulation clinics was obtained from the 2007 price
list for the Va ¨stra Go ¨taland Region, whereas the cost in
primary health care was obtained from the literature [22].
Calculations were again based on an estimated prevalence
of 140,000 AF patients. This prevalence was, in turn, based
on data from the Patient Registry and estimates of the AF
population in primary health care by the expert panel (see
‘‘Discussion’’).
Direct non-medical costs of atrial ﬁbrillation
The only direct non-medical cost included was transpor-
tation associated with hospital and primary health care
centre visits. The cost for transportation to and from
Swedish hospitals was obtained from a previous study [23].
Transportation costs related to hospitalizations were
assumed to be twice that of a hospital outpatient visit. The
rationale being the health state of such patients normally
requires transportation by taxi or the assistance of a care-
taker. Primary health care centres, on the other hand, are
generally more accessible and, therefore, transportation
costs were calculated as half the cost of a hospital outpa-
tient visit.
Direct costs of complications
The direct costs of complications of AF included stroke
and HF. As AF is a strong single risk factor for stroke, all
such events were assumed to be due to AF in patients with
a previous diagnosis of this cardiac arrhythmia. According
to published literature and national guidelines (based on
data from the Swedish National Registry for Stroke Care;
Riks-Stroke), 20% of all strokes are related to AF [24, 25].
The number of hospitalized patients diagnosed with stroke
was obtained from the open statistical database at the
Swedish National Board of Health and Welfare (available
at: http://www.socialstyrelsen.se). The direct cost of stroke
was adapted from a previous Swedish study by Ghatnekar
et al. [26], reporting on the direct life-time costs of stroke
based on the incidence approach. Further research from the
same group showed that ﬁrst-ever stroke accounts for 73%
of all stroke events [27]. Thus, the annual direct cost of AF-
related stroke in the present study was calculated as 73% of
the 20% of the patient population diagnosed with stroke
multiplied by the reported life-time direct costs of stroke
per patient (€61,910). This procedure is in accordance with
the method used for estimating annual costs by Ghatnekar
et al. [26].
The number of patients diagnosed with HF was calcu-
lated from a prevalence of 2% [28–30] of the Swedish
population. Additionally, we estimated that 22% of patients
with HF had a previous diagnosis of AF that played a
signiﬁcant causal role. This estimation was calculated from
two publications reporting a causal factor of 20 and 24%,
respectively [31, 32]. The direct cost of HF was estimated
according to data from a study by Agvall et al. [33], where
the annual cost per patient was assessed to €4,358.
Indirect costs
Indirect costs included production loss due to (1) sick leave
for longer periods than 14 days as those are the only being
centrally registered, (2) hospitalizations for AF and its
main complications stroke and HF, and (3) hospital out-
patient and primary health care visits related to AF per se.
These costs were applied to patients\65 years of age, the
usual Swedish retirement age.
The cost of production loss was estimated from an
average salary of €161.62 per day in the Swedish popula-
tion, including employer contributions. The number of
patients on sick leave for 2007, including the average
absence, was retrieved from the Swedish Social Insurance
Agency. Absence from work when hospitalized was cal-
culated from the average number of hospitalization days
(from the open statistical database at the Swedish National
Board of Health and Welfare). A visit to a hospital out-
patient clinic or primary health care centre, including
transportation, was estimated at two hours.
Data analysis
Data from national registries are presented descriptively
with mean and standard deviation (SD) calculated for rel-
evant variables. For some variables, point estimates were
applied from public reports, databases, published literature,
or an expert panel. Results are presented in a disaggregated
manner to facilitate comparison with other data sources.
Results
Patient population
A total number of 100,557 individuals had AF as a primary
(C1/3) or secondary diagnosis at hospitalization or hospital
outpatient care. This number corresponds to a prevalence of
1.1% of the Swedish population. The mean (SD) age was
74.9 (12.1) years, 78.1 (10.8) years for women, and 72.3
(12.3) years for men. Among these individuals, there were
81,364 (81%) in the age C65 years and 44% were women.
Figure 1 shows the proportion of women and men
among patients with AF as the primary or secondary
diagnosis and hospitalized or treated in hospital outpatient
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123care (n = 100,557), by age subgroup. Figure 2 shows the
proportion of women and men with AF as the primary or
secondary diagnosis as a percentage of the entire Swedish
population for each age interval.
There were 123,192 hospitalizations, 105,210 (85%)
among patients aged C65 years. Twenty-six percent
(32,569) of the hospitalizations had a primary diagnosis of
AF. The total number of hospital outpatient visits was
80,855, of those 55,828 (69%) were among patients
C65 years of age. Sixty-seven percent (54,218) of the
hospital outpatient visits were made by patients with a
primary AF diagnosis.
The mean (SD) number of hospitalizations per individ-
ual with AF as primary diagnosis was 1.49 (1.22) among
those aged \65 and 1.32 (0.83) among those aged C65.
The corresponding number of hospital outpatient visits was
1.78 (2.06) and 1.54 (1.61), respectively.
Direct costs of atrial ﬁbrillation
The annual direct costs of AF are shown in Table 1
including details of the type of hospitalization and hospital
outpatient visit from the Patient Registry. Table 1 also
shows the estimates for primary health care, AF as sec-
ondary diagnosis, pharmaceuticals, anticoagulation moni-
toring, and transportation.
The number of hospitalizations for patients diagnosed
with AF as secondary diagnosis was 90,623. A primary
diagnosis of myocardial infarction, other ischaemic heart
disease, valve disorders, or diabetes mellitus result in an
Fig. 1 Proportion of women
and men in patients with atrial
ﬁbrillation (n = 100,557), by
age subgroups
Fig. 2 Proportion of women
and men in patients with atrial
ﬁbrillation, as a percentage of
the Swedish population for each
age interval
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123extra DRG cost ranging from €206 to €2,230 when
accompanied by a secondary diagnosis of AF. Some dis-
orders such as hypertension, angina pectoris, hyperlipida-
emia, on the other hand, do not result in higher costs with
AF as secondary diagnosis. Taking all those diagnoses into
account, the average extra cost of having AF as secondary
diagnosis when hospitalized for a different reason was
estimated at €685. Applying this assumption, the resulting
cost for all 90,623 hospitalizations was €62.05 million
annually.
The annual cost of pharmaceuticals was €19.27 million,
including rate control agents €9.41 million, rhythm control
agents €3.16 million, and antithrombotic treatment with
warfarin €5.52 million and ASA €1.19 million.
The annual direct medical and non-medical costs of AF,
excluding its complications, were estimated at €212.30
million and €28.01 million, respectively.
Direct costs of complications
The annual cost of stroke and HF in patients with a pre-
vious diagnosis of AF was based on data from the pub-
lished literature (see ‘‘Methods’’). The annual cost of stroke
was estimated at €208.64 million and HF at €176.07
million.
Indirect costs
Table 2 shows the indirect costs of production loss due to
AF and its main complications stroke and HF. During
2007, 1,093 cases of sick leave due to AF, with an average
duration of 230 days, were reported in Sweden. Stroke I63
resulted in 1,625 cases with an average of 403 days
(365 days applied in the analysis), whereas there were 246
cases for stroke I64 with an average of 353 days. There
Table 1 The annual direct medical and non-medical costs of atrial ﬁbrillation (AF) in Sweden
Resources Unit cost (€) Annual no. Annual cost (€ million) Sources
Direct medical costs
Hospitalization (inpatient care) 62.00
Electrical cardioversion 1,233 8,600 10.60 [a]
Hospitalization, unspeciﬁed 1,233 22,560 27.82 [a]
Catheter ablation 11,485 857 9.84 [a]
His-ablation incl pacemaker 9,488 222 2.11 [a]
Maze surgery 35,234 77 2.71 [a]
Other surgery for AF 35,234 253 8.91 [a]
Hospital outpatient care 21.51
Visit to a specialist 328 47,324 15.54 [b]
Electrical cardioversion 824 6,811 5.61 [a]
Pacemaker or deﬁbrillator
c 4,267 83 0.35 [a]
Visit to a general practitioner 118 54,218 6.39 [d]
AF as secondary diagnosis 685 90,623 62.05 [a]
Pharmaceuticals n.a. n.a. 19.27 [e]
Anticoagulation monitoring 23/62 1,047,801 41.09 [f]
Direct non-medical costs
Transportation 14.5/29/58 1,188,806 28.01 [g]
Total direct cost of AF
h 240.31
a Unit costs from DRG (Diagnosed Related Groups). Annual no. from the Patient Registry at the Swedish National Board of Health and Welfare
b Unit cost from a medical price list (‘‘Utomla ¨nsprislista’’) for the Va ¨stra Go ¨taland Region. Annual no. from the Patient Registry at the Swedish
National Board of Health and Welfare
c Insertion, change or removal of pacemaker or deﬁbrillator, short therapy (hospital outpatient procedure)
d Unit cost from a medical price list (‘‘Utomla ¨nsprislista’’) for the Va ¨stra Go ¨taland Region. Annual no. estimated by an expert panel
e Unit costs from reference [21]. Annual no. based on references [17–20]
f Unit costs (anticoagulation clinic/primary health care) from a medical price list (‘‘Utomla ¨nsprislista’’) for the Va ¨stra Go ¨taland Region, and
reference [22]. Annual no. based on references [18–20, 22]
g Unit costs (primary health care/hospital outpatient care/hospitalization) based on reference [23]. Annual no. from the Patient Registry,
estimates from an expert panel, and references [18–20, 22]
h Cost of complications (stroke and heart failure) not included
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123were 685 cases due to HF, with an average of 286 days.
The annual cost of sick leave due to AF, including stroke
and HF, was estimated at €69.54 million.
Production loss during hospitalization resulted in an
annual cost of €4.10 million for all three diagnoses. In
addition, the annual cost of production loss during visits to
a specialist or general practitioner and to anticoagulation
monitoring centres among AF patients of working age was
estimated at €9.65 million.
Total costs
Table 3 summarizes the estimated total direct medical and
non-medical as well as indirect costs of AF and its main
complications stroke and HF. The annual total cost of AF
including stroke and HF was €708 million, where the total
direct and indirect costs of AF represent €293 million and
complications €415 million.
Discussion
This is a comprehensive analysis of the annual direct and
indirect costs of AF where relevant data have been derived
from national registries covering the entire Swedish pop-
ulation of more than nine million people. The total cost of
AF and its main complications stroke and HF was esti-
mated at €708 million, corresponding to €77 per inhabitant.
The major cost driver was the direct cost of complications
(€385 million; 54%), followed by hospitalizations due to
AF including AF as secondary diagnosis (€124 million;
18%), and production loss (€83 million; 12%).
As shown in Fig. 1, the prevalence of AF increases with
age in accordance with previous data [2]. Among those
aged C80, the increase was apparent only in women pos-
sibly explained by this age group being the most rapidly
growing with women tending to live longer than men [3].
As a consequence of the ageing population, AF-related
resource costs within health care as well as social services
will most likely escalate in the future [2].
The AF prevalence of 1.1% in the Swedish population,
based on the 100,557 individuals identiﬁed with AF either
as primary or as secondary diagnosis in hospital care,
represents the lower limit. There are no reliable ﬁgures on
the total prevalence of AF available for Sweden to date. It
has, however, been documented that approximately one-
third of AF patients and more than 50% of paroxysmal
episodes are asymptomatic [34]. Furthermore, there are
additional patients with no hospital contact or treatment in
primary health care, the number of which can only be
assumed. Approximations of up to 150,000 AF patients in
Sweden have been proposed [17], but the accuracy of this
Table 2 The annual indirect costs of production loss of atrial ﬁbrillation and its main complications stroke and heart failure in Swedish patients
younger than 65
Resources Annual no. Annual cost (€ million)
a Sources
Sick leave 69.54
Atrial ﬁbrillation 251,171
b 40.59 [c]
Complications (stroke and heart failure) 179,094
b 28.95 [d]
Hospitalization 4.10
Atrial ﬁbrillation 14,953
b 2.42 [e]
Complications (stroke and heart failure) 10,425
b 1.68 [e]
Hospital outpatient and primary health care visits 238,666 9.65 [f]
Total indirect cost 83.29
a All costs of production loss were estimated from an average Swedish salary (€161.62 per day)
b No. of days
c Annual no. from the Swedish Social Insurance Agency
d Annual no. from the Swedish Social Insurance Agency, with adaptations from references [24–32]
e Annual no. from the open statistical database at the Swedish National Board of Health and Welfare
f Annual no. from the Patient Registry at the Swedish National Board of Health and Welfare, estimates from an expert panel, and references [18–
20, 22]. Two hours per visit; complications not included (not available)
Table 3 The annual total direct and indirect costs of atrial ﬁbrillation
and its main complications stroke and heart failure, in Sweden
Resources Annual cost
(€ million)
Direct medical cost of atrial ﬁbrillation 212.3
Direct non-medical cost of atrial ﬁbrillation 28.0
Direct cost of complications (stroke and heart
failure)
384.7
Indirect cost of atrial ﬁbrillation 52.7
Indirect cost of complications (stroke and heart
failure)
30.6
Total cost 708
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123number is uncertain. In this study, we estimated the prev-
alence of AF in Sweden at approximately 140,000. This
estimate was used in the calculations of the costs for
pharmaceuticals and anticoagulation monitoring, thus rep-
resenting a minor part of the total cost.
Based on the total cost of AF of €708 million, the annual
cost per patient in Sweden would be €4,722 with a prev-
alence of 150,000, whereas the corresponding cost for a
prevalence of 140,000 would be €5,059. In a sub-study of
the Euro Heart Survey on AF, which included ﬁve Euro-
pean countries, the average annual per-patient cost ranged
from €1,010 to €3,225 [12]. Furthermore, a previous
French cost of care survey reported an annual cost per
patient of €3,209 [9] and, in another French cost analysis
based on clinical and economic literature, the annual cost
of AF was estimated at €3,308 per patient [35]. In contrast,
two other studies have reported lower annual costs.
A German study estimated the annual per-patient cost at
€827 [10], whereas in a study from the United Kingdom the
estimated direct cost of health care, including nursing
homes, in patients with primary diagnosis of AF was
approximately €779 per patient [13]. However, none of the
above-cited studies included all the various resource items
and their associated costs considered in the present study.
The studies reporting a lower per-patient cost did, for
example, not include the cost of stroke [13] and/or HF
[10, 13]. In addition, indirect costs due to production loss
were only considered in two of the studies [9, 12]. How-
ever, health care management varies between countries and
so does the timing of the studies, thus limiting the trans-
ferability across both country borders and periods of time.
The total cost of AF presented herein is considerably
higher than shown in a previous cost-of-illness analysis
based on a sub-set (just over 400,000 people) of the
Swedish population [18]. However, that report included
only costs of anticoagulation treatment and of stroke as a
complication of AF, and may therefore not be appropriate
for a direct cost comparison.
To put the total annual cost of AF (€708 million) in a
wider perspective, the present data were compared with cost
analyses forother diseases in Sweden. Ina previousanalysis
of stroke, the direct and indirectannual costs were estimated
at €1,330 million [26]. Furthermore, the annual direct
medical cost of HF was estimated at €541 to €724 million
[33], whereas the estimated direct and indirect costs of
diabetes mellitus was €621 million [15], depression €378
million [36], breast cancer €324 million [37], and osteopo-
rosis €610 million [38]. As expected, costs vary between
diseases,whichmayreﬂecttruedifferencesincosts,butmay
also reﬂect differences in the approach of the analyses and
that the data were based on previous years.
The ICD-10 codes for subarachnoid and cerebral
haemorrhages (I60 and I61) were not included, which may
have resulted in an underestimation of the cost of stroke if
induced by AF-motivated anticoagulation therapy. How-
ever, haemorrhages only affect a minor part of the AF
population and some haemorrhages will be covered under
I64, ‘‘Unspeciﬁed stroke’’.
AF as primary diagnosis deﬁned the total number of
hospitalizations and hospital outpatient visits from the
Patient Registry, whereas the speciﬁc data on non-phar-
macological interventions were based on AF either as
primary or as secondary diagnosis. This may imply an
underestimation of the cost of AF regarding both hospi-
talizations and hospital outpatient care. There were, for
example, 90,623 hospitalizations where AF was the sec-
ondary diagnosis. It is unknown to what degree AF was
truly the secondary diagnosis or whether it should have
been the primary diagnosis, as the extent of which mis-
coding of diagnosis takes place in Swedish hospitals is
unknown. In an attempt to somewhat alleviate this poten-
tial underestimation, and also to account for the extra costs
associated with AF when hospitalized for a different rea-
son, an extra cost for all hospitalizations where AF was
listed as secondary diagnosis was included. It is unlikely
that AF was added as a secondary diagnosis unless it was
considered of clinical importance.
The number of electrical cardioversions may have been
underestimated in the present report, since these were
registered with the so-called KVA ˚ (‘‘Kirurgiska
Va ˚rda ˚tga ¨rder’’) codes, and there is not as yet full coverage
of these codes in the Patient Registry. Some electrical
cardioversions were probably, however, also included in
‘‘unspeciﬁed hospitalizations’’.
The use of rate as well as rhythm control agents was
estimated from the Auricula Registry, which includes a
somewhat sicker population, mostly in specialist care.
These data may, therefore, not be applicable to an average
AF population (expert panel). However, the annual cost of
all pharmaceuticals as presented herein, only accounts for
about 3% of the total cost of AF, and therefore has only a
minor impact on the result.
The average length of sick leave reported herein may
appear quite long for AF patients of working age. It con-
cerns, however, a small fraction of the total number of AF
patients, roughly 6% of individuals under 65. Those on
long-term sick leave may have a severe symptomatic AF
and/or been subjected to or waiting for a non-pharmaco-
logical intervention. In Sweden, sick-leave periods shorter
than 14 days are covered by employers and are not cen-
trally registered. We captured the long-term sick-leave
periods from The Swedish Social Insurance Agency and
allocated sick leave to patients for the duration of hospital
stay, but any sick leave beyond that was not included due
to unavailability of information. The cost of sick leave
was therefore underestimated. Neither the costs of early
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123retirement nor premature mortality was included, thus
representing yet another underestimation of the indirect
costs of AF.
In conclusion, we have estimated the total cost of AF in
Sweden at €708 million annually. We have used, to our
knowledge, the best available sources of information, but
our research implies that the results underestimate the true
costs and future research should aim to ﬁll the gaps in the
analysis.
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